[Antithymocyte globulin used for treatment of severe acute graft versus host disease after haploidentical bone marrow transplantation].

Abstract

The objective of study was to investigate the effect of low-dose antithymocyte globulin (ATG) on steroid-resistant severe acute graft versus host disease (aGVHD). Six patients with steroid-resistant severe aGVHD after haploidentical bone marrow transplantation (BMT) received the treatment with ATG at a low dose of 1.25 mg/kg for 3 - 5 doses every other day. The results showed that 3 out of 6 patients got completely remission (CR), among them 2 patients have still been in disease-free survival, 1 patient died from leukemia relapse. 1 out of the other 3 patients got partial remissin (PR), 2 patients were aggravated. The other 3 patients all died from GVHD. The major complications observed in these patients were infections. In conclusion, low-dose ATG is effective for some patients with steroid-resistant severe aGVHD, and has not severe side effect. To strengthen environmental protection should be considered as important for prevention of infection.

• Authors: Jing Liu, Heng-Xiang Wang, Lian-Ning Duan, Mei Xue, Ling Zhu, Hong-Min Yang, Li Ding, Shu-Quan Ji
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 15 Issue 4 Pg. 816-8 (Aug 2007) ISSN: 1009-2137 [Print] China
• PMID: 17708810 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antilymphocyte Serum
• HLA Antigens

Topics

• Adolescent
• Adult
• Antilymphocyte Serum (administration & dosage)
• Bone Marrow Transplantation (adverse effects)
• Child
• Female
• Graft vs Host Disease (drug therapy, etiology)
• HLA Antigens (immunology)
• Haplotypes (immunology)
• Humans
• Male
• Young Adult